Vitestro appoints medtech executive Eliane Schutte to its Board of Directors
Vitestro is proud to announce the appointment of Eliane Schutte to its Board of Directors as a non-executive, independent director.
Eliane brings more than 25 years of global leadership experience across MedTech and biotech, with deep expertise in product development, clinical strategy, quality assurance, regulatory affairs, and commercialization. As CEO of Xeltis, she has helped strengthen the company’s strategic direction across vascular applications, led major financing and strategic licensing initiatives totaling more than €110 million, and advanced the organization into pivotal clinical trials in preparation for market approvals and commercialization. She joined Xeltis in 2015 as Chief Development Officer, where she led clinical development, product development, and regulatory strategy.
Prior to Xeltis, Eliane held senior leadership roles including Vice President of Global Product Development at The Medicines Company, Chief Development Officer at Profibrix, Founder and owner of Signifix, a quality assurance and regulatory affairs (QA/RA) consulting firm, and Vice President of Regulatory Affairs at IsoTis Orthobiologics, a publicly traded company later acquired. Earlier in her career, she held quality engineering roles at Medtronic.
Eliane’s extensive experience in quality assurance, regulatory affairs, clinical development, and scaling innovative healthcare technologies from development through commercialization further strengthens Vitestro’s Board as we continue advancing autonomous robotic phlebotomy and preparing for broader market expansion.
“We are excited to welcome Eliane to the Vitestro Board of Directors,” said Toon Overbeeke, CEO and Co-founder of Vitestro. “Her deep expertise in clinical development, regulatory strategy, and the commercialization of breakthrough medical technologies will be invaluable as we continue advancing the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™) across Europe and ultimately the United States.”
“Vitestro is pioneering an important new category in laboratory automation at a time when healthcare systems around the world are facing increasing operational and staffing pressures,” said Eliane Schutte. “I look forward to working alongside the Board and leadership team as the company advances autonomous robotic phlebotomy and continues building the clinical, regulatory, and commercial foundation for long term global growth.”
We look forward to the strategic insights and guidance Eliane will provide alongside our Board and leadership team as Vitestro continues its mission to help enable the future of total laboratory workflow automation, help mitigate the global staffing shortage, and improve the patient experience through innovation.